Cardiol Therapeutics Sets June 24, 2026 Virtual AGM and Adopts Notice-and-Access for Proxy Materials
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an announcement.
Cardiol Therapeutics has called its annual general meeting of shareholders for June 24, 2026, to be held exclusively online, with May 7, 2026 set as the record date for voting eligibility. Investors will review the audited 2025 financial statements, elect directors, and vote on appointing BDO Canada LLP as auditor for the 2026 fiscal year.
The company is using Canadian notice-and-access rules to distribute its proxy circular and 2025 financial disclosures electronically via SEDAR+ and its website, while offering paper copies on request to cut postage costs and reduce environmental impact. Shareholders are required to submit proxies or voting instructions at least 48 hours before the meeting, underscoring Cardiol’s push toward a fully digital, efficiently administered governance process.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is primarily weighed down by weak financial performance (pre-revenue, sizable losses, and material cash burn despite low leverage). Technicals are mildly supportive on longer-term moving averages but not strong, and valuation signals remain challenged due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a Canada-based biopharmaceutical company focused on developing therapies for cardiovascular diseases. The company’s shares are listed in both Canada and the U.S., and it reports under the Canadian Form 40-F regime while communicating with investors through Canadian disclosure systems such as SEDAR+.
Average Trading Volume: 137,627
Technical Sentiment Signal: Buy
Current Market Cap: C$203.6M
Learn more about CRDL stock on TipRanks’ Stock Analysis page.
